Literature DB >> 23343652

Nasal high-mobility group box-1 protein in children with allergic rhinitis.

C Salpietro1, C Cuppari, L Grasso, M A Tosca, M Miraglia Del Giudice, M La Rosa, G L Marseglia, A Salpietro, G Ciprandi.   

Abstract

BACKGROUND: Allergic rhinitis (AR) is characterized by an inflammatory reaction. High-mobility group box-1 protein (HMGB1) has many characteristics similar to classic proinflammatory cytokines. No study has yet investigated its role in AR. The aim of this study was to measure HMGB1 levels in the fluid recovered from nasal lavage in children with untreated AR and in control subjects. MATERIALS: The study was conducted on 104 AR subjects (48 males and 56 females, median age 10.3 ± 3.4 years) and 97 healthy children (42 males and 55 females) who were age-matched (median age 9.8 ± 4.1 years). Total serum immunoglobulin E, peripheral eosinophils and nasal symptoms assessed by visual analog scale (VAS) were considered. HMGB1 was measured using an ELISA assay.
RESULTS: HMGB1 levels in nasal lavage fluid were higher in AR children than in the control group (96.9 ± 19.3 vs. 9.27 ± 4.01 ng/ml; p < 0.001). There was a very strong relationship between HMGB1 levels and VAS values in AR children (r = 0.919). Considering the symptom severity assessed by VAS, there was a relationship between HMGB1 and VAS in all AR subgroups: more evident in the severe subgroup (r = 0.727).
CONCLUSIONS: Nasal HMGB1 has significantly increased in children with AR and is significantly related to symptom severity.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343652     DOI: 10.1159/000345246

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  14 in total

Review 1.  Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.

Authors:  L Keith Scott; Robert Toner
Journal:  Lung       Date:  2017-06-16       Impact factor: 2.584

2.  Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release.

Authors:  Shan Chen; Yanjun Wang; Guoqing Gong; Jianjun Chen; Yongzhi Niu; Weijia Kong
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

Review 3.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

4.  Increase in the Level of Proinflammatory Cytokine HMGB1 in Nasal Fluids of Patients With Rhinitis and its Sequestration by Glycyrrhizin Induces Eosinophil Cell Death.

Authors:  Leonardo Cavone; Caterina Cuppari; Sara Manti; Luisa Grasso; Teresa Arrigo; Luca Calamai; Carmelo Salpietro; Alberto Chiarugi
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-05-13       Impact factor: 3.372

Review 5.  Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".

Authors:  Sara Manti; Claudio Romano; Valeria Chirico; Martina Filippelli; Caterina Cuppari; Italia Loddo; Carmelo Salpietro; Teresa Arrigo
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

6.  Physiologic concentrations of HMGB1 have no impact on cytokine-mediated eosinophil survival or chemotaxis in response to Eotaxin-2 (CCL24).

Authors:  Kimberly D Dyer; Helene F Rosenberg
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

7.  Impact of Histone H1 on the Progression of Allergic Rhinitis and Its Suppression by Neutralizing Antibody in Mice.

Authors:  Toshiaki Nakano; Rikiya Kamei; Takashi Fujimura; Yuki Takaoka; Ayane Hori; Chia-Yun Lai; Kuei-Chen Chiang; Yayoi Shimada; Naoya Ohmori; Takeshi Goto; Kazuhisa Ono; Chao-Long Chen; Shigeru Goto; Seiji Kawamoto
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

8.  High-mobility group box protein 1 expression in inflammatory diseases of the middle ear.

Authors:  Luisa Maria Bellussi; Carla Vindigni; Serena Cocca; Marie Aimee Gloria Munezero Butorano; Walter Livi; Giulia Corallo; Desiderio Passali
Journal:  Int J Immunopathol Pharmacol       Date:  2017-03-15       Impact factor: 3.219

Review 9.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

Review 10.  HMGB1 in the Pathogenesis of Nasal Inflammatory Diseases and its Inhibition as New Therapeutic Approach: A Review from the Literature.

Authors:  Luisa Maria Bellussi; Serena Cocca; Giulio Cesare Passali; Desideri Passali
Journal:  Int Arch Otorhinolaryngol       Date:  2017-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.